<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ashkani EG</submitter><funding>NCI NIH HHS</funding><pagination>195</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12944968</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(2)</volume><pubmed_abstract>&lt;h4>Background/objectives&lt;/h4>Vaccines targeting melanoma antigens can elicit CD8&lt;sup>+&lt;/sup> T cell responses, but a growing body of work suggests CD4&lt;sup>+&lt;/sup> T cells also play a role in tumor control. Induction of CD4&lt;sup>+&lt;/sup> cells may also support B cells in producing tumor antigen-specific antibodies (Abs). We investigated Abs induced by vaccination with a cocktail of six class II MHC-restricted melanoma peptides (6MHP) and the effect of adjuvant type on Ab isotypes. We hypothesized that the vaccines would induce Abs that respond to different epitopes on individual peptides and that IgG isotype distribution varies with different vaccine adjuvants.&lt;h4>Methods&lt;/h4>Sera from patients who received a 6MHP vaccine were evaluated with enzyme-linked immunosorbent assays to map epitopes</pubmed_abstract><journal>Vaccines</journal><pubmed_title>Evaluation of Antibodies Induced by Melanoma Helper Peptide Vaccine and Their Modulation by Vaccine Adjuvants.</pubmed_title><pmcid>PMC12944968</pmcid><funding_grant_id>R21CA105777</funding_grant_id><funding_grant_id>R01CA178846</funding_grant_id><funding_grant_id>P30CA044579</funding_grant_id><funding_grant_id>R03CA219715</funding_grant_id><pubmed_authors>Ashkani EG</pubmed_authors><pubmed_authors>Taylor JJ</pubmed_authors><pubmed_authors>Olson WC</pubmed_authors><pubmed_authors>Dickinson AM</pubmed_authors><pubmed_authors>Slingluff CL</pubmed_authors></additional><is_claimable>false</is_claimable><name>Evaluation of Antibodies Induced by Melanoma Helper Peptide Vaccine and Their Modulation by Vaccine Adjuvants.</name><description>&lt;h4>Background/objectives&lt;/h4>Vaccines targeting melanoma antigens can elicit CD8&lt;sup>+&lt;/sup> T cell responses, but a growing body of work suggests CD4&lt;sup>+&lt;/sup> T cells also play a role in tumor control. Induction of CD4&lt;sup>+&lt;/sup> cells may also support B cells in producing tumor antigen-specific antibodies (Abs). We investigated Abs induced by vaccination with a cocktail of six class II MHC-restricted melanoma peptides (6MHP) and the effect of adjuvant type on Ab isotypes. We hypothesized that the vaccines would induce Abs that respond to different epitopes on individual peptides and that IgG isotype distribution varies with different vaccine adjuvants.&lt;h4>Methods&lt;/h4>Sera from patients who received a 6MHP vaccine were evaluated with enzyme-linked immunosorbent assays to map epitopes</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Feb</publication><modification>2026-07-11T03:17:05.681Z</modification><creation>2026-07-11T03:11:51.583Z</creation></dates><accession>S-EPMC12944968</accession><cross_references><pubmed>41746115</pubmed><doi>10.3390/vaccines14020195</doi></cross_references></HashMap>